For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Rituximab - Rheumatoid arthritis
PAD Profile : Rituximab - Rheumatoid arthritis Important
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Abatacept
- Certolizumab pegol
- Etanercept
- Golimumab
- Penicillamine
- Tocilizumab
- Adalimumab
- Sodium aurothiomalate
- Infliximab
- Baricitinib
- Tofacitinib
- Sarilumab
- Filgotinib
- Upadacitinib
Other Indications
- Immune thrombocytopenia
- Refractory vasculitis
- Systemic Lupus Erythematosus
- Sjogren's syndrome
- Chronic inflammatory demyelinating polyneuropathy
- Any paediatric use
- ANCA-positive vasculitis
- Connective tissue disease
- Graft versus Host Disease (GVHD)
- Myositis
- Immunoglobulin G4 related disease
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathway.
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Rheumatoid Arthritis High Cost DMARDs Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.
The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products
Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.